Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 290
- Registration Number
- NCT00887276
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Abteilung für Pneumologie, Hannover, Germany
🇩🇪Brüderkrankenhaus St. Josef , Innere Abteilung, Paderborn, Germany
🇩🇪Charité - Universitätsmedizin Berlin ,Campus Virchow-Klinikum ,Medizinische Klinik : Infektiologie u. Pneumologie, Berlin, Germany
QTc Study of Rosi XR in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00884533
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)
- Conditions
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2021-03-12
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 143
- Registration Number
- NCT00865280
- Locations
- 🇺🇸
Paratek Recruiting Site, Savannah, Georgia, United States
🇺🇸Parateck Recruiting Site, Columbus, Georgia, United States
VEG111485: A QTc Study of Pazopanib
- Conditions
- Interventions
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2
- Registration Number
- NCT00861029
- Locations
- 🇺🇸
GSK Investigational Site, Tacoma, Washington, United States
A Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2014-03-24
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 80
- Registration Number
- NCT00850746
Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2009-01-01
- Last Posted Date
- 2019-12-09
- Target Recruit Count
- 19
- Registration Number
- NCT00816426
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Pusan National Unversity Hospital (PNUH), Busan, Korea, Republic of
🇰🇷National Medical Center, Seoul, Korea, Republic of
Phase 1 Thorough QT (TQT) Study in Young Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2011-04-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT00809289
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Comparison of Moxifloxacin With Ciprofloxacin/Metronidazole on Patients With Chronic Periodontitis
- Conditions
- Interventions
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2010-05-12
- Lead Sponsor
- Facultad Nacional de Salud Publica
- Target Recruit Count
- 76
- Registration Number
- NCT00805558
- Locations
- 🇨🇴
Faculta Nacional de Salud Publica Universidad de Antioquia, Medellin, Antioquia, Colombia
A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 56
- Registration Number
- NCT00789568
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Thorough QT/QTc Study of Multiple Oral Doses of NOMAC-E2 (Org 10486 0 + Org 2317) in Healthy Women (Study 292011)(P05802)
- Conditions
- Interventions
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 189
- Registration Number
- NCT00779532
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.